Tadocizumab
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | Integrin αIIbβ3 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C2107H3252N562O673S12 |
| Molar mass | 47609.17 g·mol−1 |
  (what is this?) (verify) | |
Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.[1] It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets. [2] The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.[1]
References
- 1 2 Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
- ↑ Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M, Scott MP, Zipursky L, Darnell J (2003). Molecular cell biology (5th ed.). New York: W.H. Freeman. p. 973. ISBN 978-0-7167-4366-8.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.